Brostallicin (PNU-166196), a new minor groove DNA binder: Preclinical and clinical activity

Expert Opinion on Investigational Drugs

Volumn 18, Issue 12, 2009, Pages 1939-1946

  Lorusso, Domenica ^a   Mainenti, Sara ^a   Pietragalla, Antonella ^a   Ferrandina, Gabriella ^b   Foco, Gilda ^b   Masciullo, Valeria ^a   Scambia, Giovanni ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

Brostallicin; Chemotherapy; DNA minor groove binding agent; PNU 166196

Indexed keywords

BEVACIZUMAB; BROSTALLICIN; CETUXIMAB; CISPLATIN; DOCETAXEL; DOXORUBICIN; ERLOTINIB; GEFITINIB; GLUTATHIONE TRANSFERASE; IFOSFAMIDE; IMATINIB; IRINOTECAN; TALLIMUSTINE;

ANEMIA; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BONE MARROW TOXICITY; BREAST CANCER; CANCER CELL CULTURE; CLINICAL TRIAL; COLON CANCER; CYTOTOXICITY; DIARRHEA; DNA ALKYLATION; DNA BINDING; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL STROMAL TUMOR; GRANULOCYTOPENIA; HEAD AND NECK CANCER; HUMAN; INTESTINE OBSTRUCTION; KIDNEY CARCINOMA; KIDNEY FAILURE; LEIOMYOSARCOMA; LEUKEMIA; LEUKOPENIA; MAXIMUM TOLERATED DOSE; METABOLIC DISORDER; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHUMAN; NUTRITIONAL DISORDER; OVARY CANCER; OVARY TUMOR; PROSTATE CANCER; RECOMMENDED DRUG DOSE; REVIEW; SEPSIS; SIDE EFFECT; SOFT TISSUE SARCOMA; TERATOGENICITY; THROMBOCYTOPENIA; UTERINE CERVIX CANCER; VOMITING; WEIGHT;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; DNA; DRUG SCREENING ASSAYS, ANTITUMOR; GUANIDINES; HUMANS; MODELS, CHEMICAL; PYRROLES;

EID: 72249106025     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543780903401284     Document Type: Review

References (36)

1. D'Incalci M, Sessa C. DNA minor groove binding ligands: a new class of anticancer agents. Expert Opin Investig Drugs 17;6:875-884
2. Marchini S, Cozzi P, Beria I, et al. Sequence-specific DNA alkylation of novel tallimustine derivatives. Anticancer Drug Des 1998;13:193-205
3. Sessa C, Pagani O, Zurlo MG, et al. Phase I study of the novel distamycin derivative tallimustine (FCE 24517). Ann Oncol 1994;5:901-907
4. Broggini M, Marchini S, Fontana E, et al. Brostallicin: a new concept in minor groove DNA binder development. Anticancer Drugs 2004;15:1-6
5. D'Alessio R, Geroni C, Biasoli G, et al. Structure activity relationship of novel distamycin A derivatives: synthesis and antitumor activity. Bioorg Med Chem Lett 1994;4:1467-1472
6. Marchini S, Ciro M, Gallinari F, et al. Alpha-bromoacryloyl derivative of distamycin A (PNU 151807): a new non-covalent minor groove DNA binder with antineoplastic activity. Br J Cancer 1999;80:991-997
7. Beria I, Caldarelli M, Geroni C, et al. Cytotoxic alpha-bromoacrylic derivatives of low molecular weight. Bioorg Med Chem Lett 2002;12:1467-1471
8. Nagle CM, Chenevix-Trench G, Spurdle AB, Webb PM. The role of glutathione-S-transferase polymorphisms in ovarian cancer survival. Eur J Cancer 2007;43:283-290 (Pubitemid 46123985)
9. Ferrandina G, Scambia G, Damia G, et al. Glutathione S-transferase activity in epithelial ovarian cancer: association with response to chemotherapy and disease outcome. Ann Oncol 1997;8:343-350
10. Tagliabue G, Pifferi A, Balconi G, et al. Intracellular glutathione heterogeneity in L1210 murine leukemia sublines made resistant to DNA-interacting anti-neoplastic agents. Int J Cancer 1993;54:435-442
11. Hill BT. Collateral sensitivity and cross-resistance. Antitumor Drug Resist 1984;673-674
12. Cozzi P. A new class of cytotoxic DNA minor groove binders: alpha-halogenoacrylic derivatives of pyrrolecarbamoyl oligomers. Farmaco 2001;56:57-65
13. Meister A, Anderson ME. Glutathione. Annu Rev Biochem 1983;52:711-760
14. Fedier A, Fowst C, Tursi J, et al. Brostallicin (PNU-166196)-a new DNA minor groove binder that retains sensitivity in DNA mismatch repair-deficient tumour cells. Br J Cancer 2003;89:1559-1565
15. Geroni C, Marchini S, Cozzi P, et al. Brostallicin, a novel anticancer agent whose activity is enhanced upon binding to glutathione. Cancer Res 2002;62:2332-6
16. Beria I, Baraldi PG, Cozzi P, et al. Cytotoxic alpha-halogenoacrylic derivatives of distamycin A and congeners. J Med Chem 2004;47:2611-23
17. Nakayama M, Gonzalgo ML, Yegnasubramanian S, et al. GSTP1 CpG island hypermethylation as a molecular biomarker for prostate cancer. J Cell Biochem 2004;91:540-552
18. Broggini M, Sabatino MA, Geroni C, Weitman S. Antitumor activity of brostallicin on human prostatic cancer: role of combinatipon with hypomethylating agents. AACR-NCI-EORTC Conference on Molecular Targets, 2007; abstract A288
19. Wolkenberg SE, Boger DL. Mechanisms of in situ activation for DNA-targeting antitumor agents. Chem Rev 2002;102:2477-2495
20. Ciomei M, Pastori W, Cozzi P, Geroni MC. Induction of apoptosis with a new distamycin derivative. Proc Am Assoc Cancer Res 1999;40:1490
21. Guirouilh-Barbat J, Zhang YW, Pommier Y. Induction of glutathione-dependent DNA double-strand breaks by the novel anticancer drug brostallicin. Mol Cancer Ther 2009;8:1985-94
22. Sabatino MA, Colombo T, Geroni C, et al. Enhancement of in vivo antitumor activity of classical anticancer agents by combination with the new, glutathione-interacting DNA minor groove-binder, brostallicin. Clin Cancer Res 2003;9:5402-8
23. Nishiyama M, Yamamoto W, Park JS, et al. Low-dose cisplatin and 5-fluorouracil in combination can repress increased gene expression of cellular resistance determinants to themselves. Clin Cancer Res 1999;5:2620-8
24. Geroni C, Pesenti E, Ballinari D, et al. Combination treatment of new molecular-targeted therapies and the DNA minor groove binder brostallicin. Eur J Cancer Suppl 2004;4:95
25. Fontana E, Pignatti A. Synthesis of brostallicin (PNU-166196A) labelled with H and C. J Label Comp Radiopharm 2002;45:899-909
26. Ghielmini M, Bosshard G, Capolongo L, et al. Estimation of the haematological toxicity of minor groove alkylators using tests on human cord blood cells. Br J Cancer 1997;75:878-83
27. Ten Tije AJ, Verweij J, Sparreboom A, et al. Phase I and pharmacokinetic study of brostallicin (PNU-166196), a new DNA minor-groove binder, administered intravenously every 3 weeks to adult patients with metastatic cancer. Clin Cancer Res 2003;9:2957-64
28. Lockhart AC, Howard M, Hande KR, et al. A phase I dose-escalation and pharmacokinetic study of brostallicin (PNU-166196A), a novel DNA minor groove binder, in adult patients with advanced solid tumors. Clin Cancer Res 2004;10:468-75
29. Lorusso D, Fornari G, Caponigro F, et al. Phase I dose-escalation study of brostallicin in combination with cisplatin (cDDP) in patients with advanced solid tumors. ECCO 14
30. The European Cancer Conference 2007. Available from: http://www. CTICSeattle.com [last accessed July 2009]
31. Lorusso D, Zanaboni F, Scalone S, et al. Phase II exploratory study of brostallicin in patients with ovarian cancer resistant/ refractory to platinum-based chemotherapy. J Clin Oncol 2008;26
32. Leahy M, Ray-Coquard I, Verweij J, et al. Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2007;43:308-315 (Pubitemid 46138040)
33. Van Glabbeke M, Verweij J, Judson I, Nielsen OS. Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer 2002;38:543-549
34. Goto S, Ihara Y, Urata Y, et al. Doxorubicin-induced DNA intercalation and scavenging by nuclear glutathione S-transferase pi. FASEB J 2001;15:2702-2714
35. Ferruzzi E, Franceschini R, Cazzolato G, et al. Blood glutathione as a surrogate marker of cancer tissue glutathione S-transferase activity in non-small cell lung cancer and squamous cell carcinoma of the head and neck. Eur J Cancer 2003;39:1019-1029
36. Jeronimo C, Usadel H, Henrique R, et al. Quantitative GSTP1 hypermethylation in bodily fluids of patients with prostate cancer. Urology 2002;60:1131-1135